138 related articles for article (PubMed ID: 17936245)
1. Development and characterization of lipidic cochleate containing recombinant factor VIII.
Miclea RD; Varma PR; Peng A; Balu-Iyer SV
Biochim Biophys Acta; 2007 Nov; 1768(11):2890-8. PubMed ID: 17936245
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates.
Kosloski MP; Peng A; Varma PR; Fathallah AM; Miclea RD; Mager DE; Balu-iyer SV
Drug Deliv; 2011 May; 18(4):246-54. PubMed ID: 21114461
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A.
Ramani K; Miclea RD; Purohit VS; Mager DE; Straubinger RM; Balu-Iyer SV
J Pharm Sci; 2008 Apr; 97(4):1386-98. PubMed ID: 17705286
[TBL] [Abstract][Full Text] [Related]
4. Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model.
Ramakrishnan R; Balu-Iyer SV
J Pharm Sci; 2016 Oct; 105(10):3039-3045. PubMed ID: 27431011
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice.
Peng A; Straubinger RM; Balu-Iyer SV
AAPS J; 2010 Sep; 12(3):473-81. PubMed ID: 20517659
[TBL] [Abstract][Full Text] [Related]
6. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A.
Ramani K; Purohit V; Miclea R; Gaitonde P; Straubinger RM; Balu-Iyer SV
J Pharm Sci; 2008 Sep; 97(9):3753-64. PubMed ID: 18300296
[TBL] [Abstract][Full Text] [Related]
7. O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.
Miclea RD; Purohit VS; Balu-Iyer SV
AAPS J; 2007 Jun; 9(2):E251-9. PubMed ID: 17907766
[TBL] [Abstract][Full Text] [Related]
8. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice.
Pan J; Liu T; Kim JY; Zhu D; Patel C; Cui ZH; Zhang X; Newgren JO; Reames A; Canivel D; Jesmok G; Pierce GF; Sommer JM; Jiang H
Blood; 2009 Sep; 114(13):2802-11. PubMed ID: 19654409
[TBL] [Abstract][Full Text] [Related]
9. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation.
Turecek PL; Bossard MJ; Graninger M; Gritsch H; Höllriegl W; Kaliwoda M; Matthiessen P; Mitterer A; Muchitsch EM; Purtscher M; Rottensteiner H; Schiviz A; Schrenk G; Siekmann J; Varadi K; Riley T; Ehrlich HJ; Schwarz HP; Scheiflinger F
Hamostaseologie; 2012; 32 Suppl 1():S29-38. PubMed ID: 22961422
[TBL] [Abstract][Full Text] [Related]
10. Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice.
Ramakrishnan R; Davidowitz A; Balu-Iyer SV
J Pharm Sci; 2015 Aug; 104(8):2451-6. PubMed ID: 26038127
[TBL] [Abstract][Full Text] [Related]
11. Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice.
Kosloski MP; Pisal DS; Mager DE; Balu-Iyer SV
Biopharm Drug Dispos; 2014 Apr; 35(3):154-63. PubMed ID: 24259187
[TBL] [Abstract][Full Text] [Related]
12. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
[TBL] [Abstract][Full Text] [Related]
13. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.
Kosloski MP; Miclea RD; Balu-Iyer SV
AAPS J; 2009 Sep; 11(3):424-31. PubMed ID: 19499345
[TBL] [Abstract][Full Text] [Related]
14. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
[TBL] [Abstract][Full Text] [Related]
15. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.
Peng A; Kosloski MP; Nakamura G; Ding H; Balu-Iyer SV
AAPS J; 2012 Mar; 14(1):35-42. PubMed ID: 22173945
[TBL] [Abstract][Full Text] [Related]
16. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.
Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL
Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754
[TBL] [Abstract][Full Text] [Related]
17. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.
Purohit VS; Ramani K; Sarkar R; Kazazian HH; Balasubramanian SV
J Biol Chem; 2005 May; 280(18):17593-600. PubMed ID: 15728582
[TBL] [Abstract][Full Text] [Related]
18. Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.
Gaitonde P; Purohit VS; Balu-Iyer SV
Eur J Pharm Sci; 2015 Jan; 66():157-62. PubMed ID: 25459532
[TBL] [Abstract][Full Text] [Related]
19. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII.
Toschi V
Curr Opin Mol Ther; 2010 Oct; 12(5):617-25. PubMed ID: 20886394
[TBL] [Abstract][Full Text] [Related]
20. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
Lei TC; Scott DW
Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
